- Home
- BMY vs CME Comparison
BMY vs CME Comparison
Compare BMY & CME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMY | CME |
|---|---|---|
| Founded | 1887 | 1898 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3B | 98.5B |
| IPO Year | N/A | 2002 |
Fundamental Metrics
Financial Performance| Metric | BMY | CME |
|---|---|---|
| Price | $54.72 | $276.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 12 |
| Target Price | $56.31 | ★ $285.92 |
| AVG Volume (30 Days) | ★ 16.2M | 1.7M |
| Earning Date | 02-05-2026 | 02-04-2026 |
| Dividend Yield | ★ 4.61% | 3.90% |
| EPS Growth | N/A | ★ 8.52 |
| EPS | 2.97 | ★ 10.32 |
| Revenue | ★ $48,034,000,000.00 | $6,385,200,000.00 |
| Revenue This Year | $0.27 | $7.30 |
| Revenue Next Year | N/A | $4.74 |
| P/E Ratio | ★ $18.39 | $26.81 |
| Revenue Growth | 1.26 | ★ 5.81 |
| 52 Week Low | $42.52 | $224.62 |
| 52 Week High | $63.33 | $290.79 |
Technical Indicators
Market Signals| Indicator | BMY | CME |
|---|---|---|
| Relative Strength Index (RSI) | 69.18 | 55.36 |
| Support Level | $54.01 | $264.80 |
| Resistance Level | $54.86 | $276.51 |
| Average True Range (ATR) | 1.06 | 4.68 |
| MACD | 0.05 | 0.45 |
| Stochastic Oscillator | 89.49 | 91.23 |
Price Performance
Historical ComparisonAbout BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
About CME CME Group Inc.
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indices, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.